@article {Rioux936, author = {Nathalie Rioux and Lorna H. Mitchell and Philip Tiller and Katie Plant and Joanne Shaw and Kerry Frost and Scott Ribich and Mikel P. Moyer and Robert A. Copeland and Richard Chesworth and Nigel J. Waters}, title = { Structural and Kinetic Characterization of a Novel N-acetylated Aliphatic Amine Metabolite of the PRMT Inhibitor, EPZ011652 }, volume = {43}, number = {7}, pages = {936--943}, year = {2015}, doi = {10.1124/dmd.115.064014}, publisher = {American Society for Pharmacology and Experimental Therapeutics}, abstract = {Pharmacokinetic and metabolite identification studies were conducted to understand the clearance pathways of EPZ011652 [(2-aminoethyl)(methyl)({3-[4-(propan-2-yloxy)phenyl]-1H-pyrazol-4-yl}methyl)amine], a potent protein arginine N-methyltransferase inhibitor. Metabolic clearance was the major pathway of EPZ011652 elimination in rats with structural elucidation of metabolites via liquid chromatography - mass spectrometry (LC-MSn) accurate mass measurement revealing the formation of a novel aliphatic N-acetylated metabolite (M1) located on the terminal nitrogen of the ethylene-diamine side chain. EPZ015564, a synthetic standard of the N-acetyl product, was prepared and was also generated by human and rat, but not dog hepatocytes. In rat hepatocytes, on incubation with EPZ011652, the concentration of EPZ015564 initially increased before decreasing with incubation time, suggesting that the metabolite is itself a substrate for other metabolizing enzymes, in agreement with the identification of metabolites M2, M3, and M4 in rat bile, all N-acetylated metabolites, undergoing sequential phase I (demethylation, oxidation) or phase II (sulfation) reactions. Reaction phenotyping with recombinant human N-acetyltransferase (NAT) isoforms revealed that both NAT1 and NAT2 are capable of acetylating EPZ011652, although with different catalytic efficiencies. Kinetic profiles of EPZ015564 formation followed classic Michaelis-Menten behavior with apparent Km values of \>1000 μM for NAT1 and 165 {\textpm} 14.1 {\textmu}M for NAT2. The in vitro intrinsic clearance for EPZ011652 by NAT2 (110 μL/min/mg) was 500-fold greater than by NAT1. In summary, we report the unusual N-acetylation of an aliphatic amine and discuss the implications for drug discovery and clinical development.}, issn = {0090-9556}, URL = {https://dmd.aspetjournals.org/content/43/7/936}, eprint = {https://dmd.aspetjournals.org/content/43/7/936.full.pdf}, journal = {Drug Metabolism and Disposition} }